AGLE - Aeglea BioTherapeutics, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 9.74M
Enterprise value -24.30M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.21
Price/book (mrq)0.19
Enterprise value/revenue -20.86
Enterprise value/EBITDA 0.31

Trading information

Stock price history

Beta (5Y monthly) 1.75
52-week change 3-91.46%
S&P500 52-week change 31.77%
52-week high 31.6400
52-week low 30.1340
50-day moving average 30.2039
200-day moving average 30.4914

Share statistics

Avg vol (3-month) 3767.38k
Avg vol (10-day) 3408.94k
Shares outstanding 565.4M
Implied shares outstanding 6N/A
Float 839.48M
% held by insiders 12.00%
% held by institutions 169.84%
Shares short (14 May 2023) 4432k
Short ratio (14 May 2023) 40.33
Short % of float (14 May 2023) 40.67%
Short % of shares outstanding (14 May 2023) 40.66%
Shares short (prior month 13 Apr 2023) 4712.09k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)-6,793.65%

Management effectiveness

Return on assets (ttm)-72.95%
Return on equity (ttm)-163.26%

Income statement

Revenue (ttm)1.17M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-85.50%
Gross profit (ttm)-262k
Net income avi to common (ttm)-77.8M
Diluted EPS (ttm)-0.7600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)38.48M
Total cash per share (mrq)0.59
Total debt (mrq)4.43M
Total debt/equity (mrq)13.17
Current ratio (mrq)3.51
Book value per share (mrq)0.51

Cash flow statement

Operating cash flow (ttm)-71.52M
Levered free cash flow (ttm)-45.04M